Last Price
54.64
Today's Change
-1.155 (2.06%)
Day's Change
54.11 - 58.15
Trading Volume
290,482
Market Cap
2 Billion
Shares Outstanding
37 Million
Avg Volume
355,279
Avg Price (50 Days)
49.57
Avg Price (200 Days)
52.27
PE Ratio
-10.65
EPS
-5.13
Earnings Announcement
04-Nov-2024
Previous Close
55.80
Open
58.15
Day's Range
54.11 - 58.15
Year Range
27.02 - 73.0
Trading Volume
290,557
1 Day Change
-2.07%
5 Day Change
-0.72%
1 Month Change
20.07%
3 Month Change
17.67%
6 Month Change
-17.04%
Ytd Change
26.70%
1 Year Change
73.09%
3 Year Change
77.48%
5 Year Change
172.14%
10 Year Change
172.14%
Max Change
172.14%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.